Ardelyx (ARDX)
(Delayed Data from NSDQ)
$8.06 USD
-0.42 (-4.95%)
Updated May 9, 2024 04:00 PM ET
After-Market: $8.04 -0.02 (-0.25%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
ARDX 8.06 -0.42(-4.95%)
Will ARDX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ARDX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ARDX
Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates
Rigel Pharmaceuticals (RIGL) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
ARDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Ardelyx (ARDX) Reports Q4 Earnings: What Key Metrics Have to Say
Ardelyx (ARDX) Reports Q4 Loss, Lags Revenue Estimates
Other News for ARDX
Analysts Offer Insights on Healthcare Companies: Ardelyx (ARDX), Oric Pharmaceuticals (ORIC) and Cellectis SA (CLLS)
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
Ardelyx to present additional data on IBSRELA at 2024 DDW
(ARDX) - Analyzing Ardelyx's Short Interest
10 Health Care Stocks Whale Activity In Today's Session